UCB: Digital Transformation Strategies
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
UCB S.A. (UCB) is a multinational company specializing in the development and production of biopharmaceuticals for autoimmune and neurological diseases, including Psoriasis, Hidradenitis suppurativa, Myasthenia Gravis, Epilepsy, Axial Spondyloarthritis, Osteoporosis, Parkinson’s disease, CDKL5 Deficiency Disorder, Dravet syndrome, Lennox-Gastaut syndrome, Lupus, Psoriatic Arthritis, Rheumatoid Arthritis, and Thymidine Kinase 2 deficiency, among others. Some of the company’s flagship products include Briviact (for Epilepsy), Bimzelx (for Plaque psoriasis, Psoriatic arthritis, Axial spondyloarthritis, and Hidradenitis suppurativa), Cimzia (for Axial spondyloarthritis, Rheumatoid arthritis, Psoriatic arthritis, and Crohn’s disease), Vimpat (for Epilepsy), and Neupro (for Parkinson’s disease).
The report provides information and insights into UCB's tech activities, including:
• Insights of its digital transformation strategies and innovation programs.
• Overview of technology initiatives covering partnerships, and product launches.
• Insights on each technology initiative including technology theme, objective, and benefits.
• Details of estimated ICT budgets.
Scope
The report provides insights into the company’s tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
Reasons to Buy
Gain insights into UCB's tech operations.
Gain insights into its tech strategies and innovation initiatives.
Gain insights into its technology themes under focus.
Gain insights into various product launches and partnerships.
Iktos
Insilico Medicine
ZS
Accenture
Microsoft
Domino Data Lab
Bardess
Aita
BrightInsight
Cognitant Group
Veeva Systems
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals and Healthcare reports